{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:08Z","timestamp":1792206368546,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>To reduce health care costs and improve care, payers and physician groups are switching to quality-based and episodic or bundled-care models. Disease progression and associated costs may affect these models, particularly if such programs do not account for differences in disease severity and progression risk within the cohort. This study estimated the incremental cost of disease progression in patients diagnosed with chronic lymphoid leukemia (CLL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma (NHL) and compared costs among patients with and without progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective study using U.S. administrative claims data from commercial and Medicare Advantage health care enrollees with evidence of CLL, AML, and NHL and systemic antineoplastic agent use from July 1, 2006 to August 31, 2014. Outcome measures included disease progression, 12-month health care costs, and 3-year cumulative predictive health care costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 1,056 patients with CLL, 514 patients with AML, and 7,601 patients with NHL, 31.1% of patients with CLL, 63.8% of those with AML, and 36.9% of those with NHL had evidence of disease progression. Among patients with CLL and NHL, adjusted and unadjusted health care costs were significantly higher among progressors versus nonprogressors. Per-patient-per-month costs, accounting for variable follow-up time, were almost twice as high among progressors versus nonprogressors in patients with CLL, AML, and NHL. In each of the three cancer types, the longer disease progression was delayed, the lower the health care costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Progression of CLL, AML, and NHL was associated with higher health care costs over a 12-month period. Delaying cancer progression resulted in a substantial cost reduction in patients with all three cancer types.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Data on the rates and incremental health care costs of disease progression in patients with hematologic malignancies are lacking. This study estimated the incremental costs of disease progression in patients diagnosed with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma and compared health care costs in patients with and without evidence of disease progression in a real-world population. The data obtained in this study will assist future studies in quantifying the cost impact of decreased progression rates and will inform payers and physician groups about setting rates for episode and bundled payment programs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0019","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T20:35:19Z","timestamp":1551213319000},"page":"1219-1228","source":"Crossref","is-referenced-by-count":18,"title":["Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma"],"prefix":"10.1093","volume":"24","author":[{"given":"Carolina","family":"Reyes","sequence":"first","affiliation":[{"name":"Genentech, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Engel-Nitz","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"DaCosta Byfield","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arliene","family":"Ravelo","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Ogale","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bancroft","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Anderson","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Chen","sequence":"additional","affiliation":[{"name":"South Bay Oncology Hematology, San Jose, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"2021122507523187700_onco12850-bib-0001","volume-title":"Cancer Facts & Figures 2017","author":"American Cancer Society","year":"2017"},{"key":"2021122507523187700_onco12850-bib-0002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JOP.2014.001378","article-title":"Innovative payment models and measurement for cancer therapy","volume":"10","author":"Newcomer","year":"2014","journal-title":"J Oncol Pract"},{"key":"2021122507523187700_onco12850-bib-0003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021122507523187700_onco12850-bib-0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JOP.2014.001488","article-title":"Changing physician incentives for affordable, quality cancer care: Results of an episode payment model","volume":"10","author":"Newcomer","year":"2014","journal-title":"J Oncol Pract"},{"key":"2021122507523187700_onco12850-bib-0005","volume-title":"Patient-Centered Oncology Payment","author":"American Society of Clinical Oncology","year":"2015"},{"key":"2021122507523187700_onco12850-bib-0006","author":"Oncology care model","year":"2017"},{"key":"2021122507523187700_onco12850-bib-0007","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2021122507523187700_onco12850-bib-0008","volume-title":"Clinical Classifications Software for ICD-9-CM","year":"2015"},{"key":"2021122507523187700_onco12850-bib-0009","volume-title":"Consumer Price Index website","author":"U.S. Department of Labor, Bureau of Labor Statistics","year":"2012"},{"key":"2021122507523187700_onco12850-bib-0010","first-page":"126","article-title":"The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients","volume":"3313A","author":"Guerin","year":"2015","journal-title":"Blood"},{"key":"2021122507523187700_onco12850-bib-0011","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.3109\/10428194.2011.592623","article-title":"Economic impact of disease progression in follicular non-Hodgkin lymphoma","volume":"52","author":"Beveridge","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2021122507523187700_onco12850-bib-0012","first-page":"116","article-title":"Economic impact of disease progression in follicular non-Hodgkin's lymphoma","volume":"1522A","author":"Hoang","year":"2010","journal-title":"Blood"},{"key":"2021122507523187700_onco12850-bib-0013","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch Intern Med"},{"key":"2021122507523187700_onco12850-bib-0014","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10428190600573325","article-title":"Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment","volume":"47","author":"Kutikova","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2021122507523187700_onco12850-bib-0015","first-page":"114","article-title":"Impact of disease progression on healthcare cost and resource utiliation among follicular NHL patients treated within the US oncology network","volume":"4543A","author":"Gruschkus","year":"2009","journal-title":"Blood"},{"key":"2021122507523187700_onco12850-bib-0016","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-06-583765","article-title":"Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)","volume":"124","author":"Tam","year":"2014","journal-title":"Blood"},{"key":"2021122507523187700_onco12850-bib-0017","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.1988.6.2.232","article-title":"The characteristics and outcome of patients with late relapse acute myelogenous leukemia","volume":"6","author":"Kantarjian","year":"1988","journal-title":"J Clin Oncol"},{"key":"2021122507523187700_onco12850-bib-0018","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1989.7.8.1071","article-title":"Response to salvage therapy and survival after relapse in acute myelogenous leukemia","volume":"7","author":"Keating","year":"1989","journal-title":"J Clin Oncol"},{"key":"2021122507523187700_onco12850-bib-0019","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"2021122507523187700_onco12850-bib-0020","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0019","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0019","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/9\/1219\/41917770\/oncolo_24_9_1219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/9\/1219\/41917770\/oncolo_24_9_1219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:53:41Z","timestamp":1640418821000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/9\/1219\/6439289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0019","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,1]]},"published":{"date-parts":[[2019,2,26]]}}}